Effects of Therapeutic Doses of Acetaminophen in Moderate Drinkers
This study has been completed.
Sponsor:
Denver Health and Hospital Authority
Collaborator:
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Information provided by:
Denver Health and Hospital Authority
ClinicalTrials.gov Identifier:
NCT00400621
First received: November 16, 2006
Last updated: NA
Last verified: November 2006
History: No changes posted
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The study objective was to evaluate the safety of ten consecutive days of therapeutic acetaminophen dosing in moderate alcohol consumers. The main outcome was liver injury (measured by an increase in mean serum ALT or AST levels). Patients were randomly assigned to 10 days of acetaminophen or placebo. Blood tests were measured at baseline, day 4 and day 11 to look for injury. We hypothesized that there would be no difference in liver enzymes between the two groups.
| Condition | Intervention | Phase |
|---|---|---|
|
Moderate Alcohol Consumption (1-3 Drinks Per Day) |
Drug: acetaminophen |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety Study Intervention Model: Single Group Assignment Masking: Double-Blind |
| Official Title: | Assessment of Hepatic Injury in Subjects Who Consume Moderate Amounts of Alcohol While Being Administered Therapeutic Doses of Acetaminophen: |
Resource links provided by NLM:
MedlinePlus related topics:
Alcohol
Drug Information available for:
Acetaminophen
U.S. FDA Resources
Further study details as provided by Denver Health and Hospital Authority:
Primary Outcome Measures:
- mean change in serum ALT between treatment groups
Secondary Outcome Measures:
- proportion of patients that developed an abnormal ALT
- proportion of patients that developed hepatoxicity (ALT>1000 IU>L)
- proportion of patients that developed drug induced liver injury
| Estimated Enrollment: | 150 |
| Study Start Date: | April 2003 |
| Estimated Study Completion Date: | September 2003 |
Eligibility| Ages Eligible for Study: | 21 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion criteria Adult volunteers of age 21 years or older, regardless of ethnicity or gender, who provided written consent and met all three of the following criteria of a moderate alcohol consumer:
- Average baseline ethanol consumption of at least one alcoholic beverage per day before enrollment for the past two months. The estimate of ethanol intake was based on the average intake over seven days. For example, a person who ingested no alcohol on Sunday, Monday, Tuesday or Wednesday, two drinks on Thursday and four drinks on Friday and Saturday would be calculated as 10 drinks/7days = 1.4 drinks/day. The average alcoholic beverage contains 15 grams of alcohol(9).
- Average baseline ethanol consumption of no more than three alcoholic beverages (> 45 grams of alcohol) per day, calculated as a weekly average over the preceding two months.
- At least one alcohol-containing drink within the last 48 hours
Exclusion Criteria
Subjects were excluded from the study at baseline if any of the following were evident at baseline:
- Serum acetaminophen level greater than 20 mcg/ml
- Serum AST or ALT levels greater than 50 IU/L
- If female, positive for b-HCG
- Clinically intoxicated, psychiatrically impaired or unable to give informed consent
- Known hypersensitivity to acetaminophen
- History of ingesting more than four grams of acetaminophen per day for any of the four days preceding study enrollment
- Alcoholic patients as defined by those who consume on average more than three alcoholic beverages daily
- Currently enrolled in another trial or had been enrolled in another trial in the preceding three months
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00400621
Sponsors and Collaborators
Denver Health and Hospital Authority
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Investigators
| Principal Investigator: | Kennon Heard, MD | Rocky Mountain Poison Center |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00400621 History of Changes |
| Other Study ID Numbers: | COMIRB 02-999 |
| Study First Received: | November 16, 2006 |
| Last Updated: | November 16, 2006 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Denver Health and Hospital Authority:
|
acetaminophen alcohol liver injury |
Additional relevant MeSH terms:
|
Alcohol Drinking Drinking Behavior Acetaminophen Antipyretics Physiological Effects of Drugs Pharmacologic Actions |
Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Central Nervous System Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 23, 2013